Natriuretic polypeptides

• US 7,754,852 B2
• Filed: 07/18/2008
• Issued: 07/13/2010
• Est. Priority Date: 07/20/2007
• Status: Active Grant

• Current Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Original Assignee: Mayo Foundation For Medical Education And Research (Mayo Clinic)
• Inventors: Lee, Candace Y. W., Burnett, John C. Jr.
• Primary Examiner(s): Noakes; Suzanne M.
• Application Number:
  US12/175,779
• Publication Number:
  US 20090054337A1
• Time in Patent Office: 725 Days
• Field of Search: None
• US Class Current: 530/324
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 7/10 Antioedematous agents; Diuretics
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C07K 14/58 Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin

Abstract

This document provides natriuretic polypeptides. For example, this document provides polypeptides having a natriuretic activity. In some cases, a polypeptide provided herein can have natriuretic activities, while lacking the ability to lower blood pressure. This document also provides methods and materials for inducing natriuretic activities within a mammal.

Claims

1. A polypeptide less than 36 amino acid residues in length, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO;

1 or the sequence set forth in SEQ ID NO;

1 with no more than one addition, subtraction, or substitution,

(b) the sequence set forth in SEQ ID NO;

2 or the sequence set forth in SEQ ID NO;

2 with no more than two additions, subtractions, or substitutions, and

(c) the sequence set forth in SEQ ID NO;

3 or the sequence set forth in SEQ ID NO;

3 with no more than one addition, subtraction, or substitution.

2. The polypeptide of claim 1, wherein said polypeptide comprises natriuretic activity.

3. The polypeptide of claim 1, wherein said polypeptide lacks the ability to induce systemic hypotension.

4. The polypeptide of claim 1, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO;

1,

(b) the sequence set forth in SEQ ID NO;

2 or the sequence set forth in SEQ ID NO;

2 with no more than two additions, subtractions, or substitutions, and

(c) the sequence set forth in SEQ ID NO;

3 or the sequence set forth in SEQ ID NO;

3 with no more than one addition, subtraction, or substitution.

5. The polypeptide of claim 1, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO;

1 or the sequence set forth in SEQ ID NO;

1 with no more than one addition, subtraction, or substitution,

(b) the sequence set forth in SEQ ID NO;

2, and

(c) the sequence set forth in SEQ ID NO;

3 or the sequence set forth in SEQ ID NO;

3 with no more than one addition, subtraction, or substitution.

6. The polypeptide of claim 1, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO;

1 or the sequence set forth in SEQ ID NO;

1 with no more than one addition, subtraction, or substitution,

(b) the sequence set forth in SEQ ID NO;

2 or the sequence set forth in SEQ ID NO;

2 with no more than two additions, subtractions, or substitutions, and

(c) the sequence set forth in SEQ ID NO;

3.

8. The polypeptide of claim 1, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO;

1 with no more than one addition, subtraction, or substitution,

(b) the sequence set forth in SEQ ID NO;

2 or the sequence set forth in SEQ ID NO;

2 with no more than two additions, subtractions, or substitutions, and

(c) the sequence set forth in SEQ ID NO;

3 or the sequence set forth in SEQ ID NO;

3 with no more than one addition, subtraction, or substitution.

9. The polypeptide of claim 1, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO;

1 or the sequence set forth in SEQ ID NO;

1 with no more than one addition, subtraction, or substitution,

(b) the sequence set forth in SEQ ID NO;

2 with no more than two conservative amino acid substitutions, and

(c) the sequence set forth in SEQ ID NO;

3 or the sequence set forth in SEQ ID NO;

3 with no more than one addition, subtraction, or substitution.

10. The polypeptide of claim 1, wherein said polypeptide comprises, in an order from amino terminus to carboxy terminus:

(a) the sequence set forth in SEQ ID NO;

1 or the sequence set forth in SEQ ID NO;

1 with no more than one addition, subtraction, or substitution,

(b) the sequence set forth in SEQ ID NO;

2 or the sequence set forth in SEQ ID NO;

2 with no more than two additions, subtractions, or substitutions, and

(c) the sequence set forth in SEQ ID NO;

3 with no more than one addition, subtraction, or substitution.

11. The polypeptide of claim 1, wherein said polypeptide is a substantially pure polypeptide.

16. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 1.

17. A method for increasing natriuretic activity within a mammal without lowering blood pressure, wherein said method comprises administering a polypeptide of claim 1 to said mammal.

18. A method for treating a mammal having a cardiovascular condition or renal condition, wherein said method comprises administering to said mammal a polypeptide of claim 1 under conditions wherein the severity of a manifestation of said cardiovascular condition or renal condition is reduced.

19. The method of claim 18, wherein administration of said polypeptide to said mammal does not lower the blood pressure of said mammal.

7. A polypeptide comprising the sequence set forth in SEQ ID NO:

4.

12. The polypeptide of claim 7, wherein said polypeptide comprises natriuretic activity.

13. The polypeptide of claim 7, wherein said polypeptide lacks the ability to induce systemic hypotension.

14. The polypeptide of claim 7, wherein said polypeptide is a substantially pure polypeptide.

15. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the polypeptide of claim 7.